To Treat or Watch? Identifying Drivers of Decisions for Patients with GEP-NET Using Reflective Multi-Criteria Decision Analysis

#1629

Introduction: Somatostatin analogs (SSAs) or watchful-waiting are recommended for unresectable, well- or moderately-differentiated non-functioning GEP-NET.

Aim(s): We developed a shared-decision framework and explored drivers of decision.

Materials and methods: Using a decision support tool designed from a holistic MCDA-framework (EVIDEM), literature review and patient and physician insights. 5 patients and 6 physicians explored decision drivers in 2 scenarios: SSA (reference case lanreotide) vs observation and lanreotide vs octreotide. Evidence derived from a comprehensive literature review. For each criterion, participants gave a weight, shared experiences and knowledge and assigned a score (+5 to -5 [Much in favor of option 1 vs option 2]). Criteria value contributions (VC) were calculated (NormWeightXScore) and sensitivity analyses performed.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Goetghebeur M, Samaha D, Khoury H, O'Neil W, Lavoie L,

Keywords: MCDA, decision making, GEP-NET, EVIDEM,